Advice

in the absence of a submission from the holder of the marketing authorisation:

bezlotoxumab (Zinplava®) is not recommended for use within NHS Scotland.

Indication under review: Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice135KB (PDF)

Download

Medicine details

Medicine name:
bezlotoxumab (Zinplava)
SMC ID:
1293/17
Indication:
Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
Pharmaceutical company
MSD
BNF chapter
Gastro-intestinal system
Submission type
Non submission
Status
Not recommended
Date advice published:
11 December 2017